Top
Lymphoma - Healing Genes
697
post-template-default,single,single-post,postid-697,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Lymphoma

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma


Phase 2

Line 4 DESCRIPTION:

Doctors at the Southeastern Regional Medical Center at CTCA seek participants with Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma to receive an investigatory vaccine therapy, Oncoquest-L. The vaccine contains an extract of the patient’s own cancer cells and an immune-stimulating protein, interleukin-2 (IL-2). It is hoped that when injected under the skin, the vaccine will enable the patient’s immune system to recognize and destroy the cancer cells. The trial will also assess the safety of the vaccine, the time from vaccine treatment until the patient requires another type of anti-lymphoma treatment, progression-free survival, and the anti-tumor immune response.

Participants will receive a total of 5 single injections of Oncoquest-L over 5 months, administered subcutaneously at 2 different sites in the upper arms or upper legs. Follow up will continue for ~ 2 years.


PATIENT MUST:

  • Be 18 years of age and older
  • Be diagnosed with Follicular lymphoma (FL) grade 1, 2, or 3a within 12 months of study enrollment
  • Not be pregnant
  • Willing to use contraception during the study

THE STUDY INVOLVES:

  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Participants will receive a total of 5 single injections of Oncoquest-L over 5 months: first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals
  3. Participants will receive an immune-promoting drug (IL-2)
  4. The patient will be followed closely for 2 years.

LOCATIONS AND CONTACTS:

The study site is Southeastern Regional Medical Center at CTCA in Newnan, GA. Map.

Contacts:

Karen Rados  |  770-400-6629

Mittie Mitchell, RN    |  770-400-7194

 

SPONSOR INFORMATION:

XEME Biopharma Inc.

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT02194751

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader